Share on StockTwits
 

ResMed (NYSE:RMD) Director Peter C. Farrell sold 25,000 shares of the stock in a transaction that occurred on Thursday, January 9th. The shares were sold at an average price of $48.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director now directly owns 489,876 shares in the company, valued at approximately $23,514,048. The sale was disclosed in a document filed with the SEC, which is available at this link.

ResMed (NYSE:RMD) traded down 1.99% on Monday, hitting $46.83. The stock had a trading volume of 1,057,720 shares. ResMed has a 1-year low of $41.98 and a 1-year high of $57.34. The stock’s 50-day moving average is $47.37 and its 200-day moving average is $49.35. The company has a market cap of $6.654 billion and a price-to-earnings ratio of 22.02.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, October 24th. The company reported $0.56 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.58 by $0.02. The company had revenue of $357.66 million for the quarter, compared to the consensus estimate of $372.28 million. During the same quarter in the previous year, the company posted $0.49 earnings per share. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. Analysts expect that ResMed will post $2.57 EPS for the current fiscal year.

RMD has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of ResMed from an “outperform” rating to a “neutral” rating in a research note to investors on Monday, November 4th. They now have a $59.40 price target on the stock. Separately, analysts at Jefferies Group raised their price target on shares of ResMed from $40.00 to $46.00 in a research note to investors on Friday, October 25th. They now have a “hold” rating on the stock. Finally, analysts at UBS AG upgraded shares of ResMed from a “neutral” rating to a “buy” rating in a research note to investors on Friday, October 25th. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $50.18.

ResMed Inc, (NYSE:RMD) is a holding company for the ResMed Group.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.